logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change

Summit Therapeutics PLC (LON:SUMM) CEO Glyn Edwards sat down with Proactive at the 2019 BIO Investor Forum where is explained anti microbial resistance will be as big a problem as climate change.

Edwards says recently, Summit reported that Phase II trials showed that antibiotic Ridinilazole can kill C.difficile infections while preserving healthy microorganisms in the gastrointestinal tract. Summit remains on track to deliver Phase III data for its antibiotic Ridinilazole in the second half of 2021.

Quick facts: Summit Therapeutics PLC

Price: - -

AIM:SUMM
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpha Growth PLC using experienced team to start Alpha Growth and Income...

Alpha Growth PLC (LON: ALGW) CEO Gobind Sahney joined Steve Darling from Proactive to discuss the fund called Alpha Growth and Income fund or AGI. This funds prospective client are family offices, pension funds, and other institutions that still wish to receive some income but also want their...

2 days, 9 hours ago

2 min read